Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FCM with or without rituximab in previously treated chronic lymphocytic leukemia
ISRCTN77546448Phase 2Completed
- Sponsor
- Leeds Teaching Hospitals NHS Trust
- Start
- Jul 2005
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 2, randomised, open-label trial of fludarabine, cyclophosphamide, mitoxantrone and rituximab in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (2 arms), sponsored by Leeds Teaching Hospitals NHS Trust. Started Jul 2005; status: completed.
02
Drugs
fludarabinecyclophosphamidemitoxantronerituximab
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on ISRCTN77546448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN77546448.